Loading...
NURO logo

NeuroMetrix, Inc.NasdaqCM:NURO Stock Report

Market Cap US$9.0m
Share Price
n/a
My Fair Value
n/a
1Y2.5%
7D4.7%
1D
Portfolio Value
​
View

NeuroMetrix, Inc.

NasdaqCM:NURO Stock Report

Market Cap: US$9.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NeuroMetrix (NURO) Stock Overview

A commercial stage neurotechnology company, engages in designing and sale of medical devices. More details

NURO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings have declined by 22.7% per year over past 5 years

Does not have a meaningful market cap ($9M)

Does not have meaningful revenue ($3M)


NURO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

NeuroMetrix, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for NeuroMetrix
Historical stock prices
Current Share PriceUS$4.58
52 Week HighUS$4.73
52 Week LowUS$2.66
Beta1.83
1 Month Change3.85%
3 Month Change6.26%
1 Year Change2.46%
3 Year Change-81.59%
5 Year Change-72.34%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Seeking Alpha • Oct 20

NeuroMetrix reports Q3 results

NeuroMetrix press release (NASDAQ:NURO): Q3 net loss of $1.6M Revenue of $2M (-4.8% Y/Y).
Seeking Alpha • Sep 23

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Summary DPNCheck is a screening product sold to MA insurers which gives better member health outcomes, lower cost, and increased revenue for MA insurers. The product has consistently grown >20%. Discontinuation of Quell marketing in 2018 is masking the strong, underlying growth in DPNCheck. The result is rev growth is now accelerating. Clean cap structure and balance sheet with $3.24/share which is sufficient to fund the business to profitability. Potential $15/share fair value in 5 years based on 20x FCF. For those who follow small cap med devices, NURO's business is ~85% SMLR and ~15% ZYXI. Thesis Overview The most profitable investments in microcap stocks are made when businesses reach inflection points, then go on to deliver years of organic growth and inflect to profitability. I believe that NeuroMetrix (NURO) is at that turning point. After a long history of losses and shareholder dilution from spending on R&D that didn’t work and attempts to sell medical devices that were not successful, NURO now has a clean capital structure and balance sheet with a proven business that is scaling with strong unit economics. NURO has a promising medical device called DPNCheck, which is used for early disease detection of diabetic polyneuropathy (DPN) and is sold to Medicare Advantage ((MA)) insurers with >80% of revenue from consumables. They are following the same business model as Semler Scientific (SMLR), who built a strong business by showing MA insurers that early disease detection leads to better patient outcomes, lower cost to serve patients, and increased revenue for the MA insurers through appropriately risk-coding patients. DPNCheck launched in 2011 and has grown at a >20% CAGR in recent years to $7.4m revenue in 2022. That >20% organic growth is set to continue indefinitely at ~80% gross margins. Most importantly, DPNCheck’s go-to-market is very efficient because they sell at the top level to UNH and HUM, who then push down to their organization. DPNCheck’s consistent growth and strong unit economics has been masked by NURO’s Quell product which the company sells direct-to-consumer as an over-the-counter (OTC) medical device for pain management. The company created a slick product that works well and grew it to ~$14m of revenue in 2017, but had to spend aggressively on online advertising and TV ads to get that growth (negative unit economics). In 2018, management realized their market efforts were not going to pay off for Quell because the market for TENS-like devices is too crowded, so they stopped advertising. That led to revenue declining to <$2m in 2022, which is now mostly consumable pads that are ordered by customers and paid through credit card (no insurance pay). Management pivoted the strategy for their Quell device to focusing on gaining breakthrough designation by the FDA for patients with Fibromyalgia. 10 million Americans suffer from debilitating pain from Fibromyalgia. Quell may receive FDA clearance for the device for patients with Fibromyalgia in late 2022 and begin marketing to physicians in early 2023. Having a physician prescription means they can pursue insurance reimbursement which results in a much, much higher revenue per device than selling in the highly competitive over-the-counter market. Zynex sells a prescription pain management device, but sells primarily through physical therapists and does not have specific indications or data supporting efficacy, like Quell does. The takeaways are that NURO’s revenue growth is accelerating. After revenue declines in 2018-2020 from unprofitable Quell OTC revenue falling, NURO grew 12% in 2021 and will grow 12% in 2022. I expect revenue growth to accelerate to >20% and maintain that growth for several years, primarily from DPNCheck. After significant losses from Quell advertising, NURO raised highly dilutive preferred capital in the 2016-2018 range (please refer to NURO's form 10-K filings for details). After cleaning up the cap structure, NURO raised over $20m through DRIP equity raises (selling shares directly into the market) in 2020 and 2021 (including some very attractive sales prices last year when the stock price spiked >$10/share). All this leads to an ugly and messy past, in which the share count has gone way up and the stock price way down. However, I believe that evaluating the business based on current facts, shows that NURO is an undervalued med device company that is well capitalized to pursue this growth. The company now has a clean capital structure with 7.1m shares and 0.5m options for management, no debt, no preferred, no warrants, and $23m of cash. I expect NURO to burn $3.8m in 2022, $2.7m in 2023, $1.7m in 2024, and $0.2m in 2025. Then it should start generating cash, with +$2.1m in 2026, +$4.9m in 2027. I model trough cash of $16m in 2025. On profitability, I expect the business will generate $5m of free cash flow in 2027 and be worth 20x FCF plus net cash, which gives a value of $15/share. Studying Semler’s history, once the business crossed $14m in revenue, it inflected to profitability and never looked back. DPNCheck currently has $7.4m in revenue, and I expect it to cross that threshold exiting 2025. SMLR has proven how strong the unit economics are in this business with 37% EBITDA margins in 2Q22. Revenue Mix Shift Well Underway Higher quality, more profitable DPNCheck revenue is replacing negative margin Quell revenue (when including expensive marketing spend in the past). As rev mix continues to shift, the growth will accelerate and the business will reach profitability.
Seeking Alpha • Jul 21

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix press release (NASDAQ:NURO): Q2 GAAP EPS of -$0.17. Revenue of $2.1M (-5.0% Y/Y).
Analysis Article • May 11

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 19

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Sep 09

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

NeuroMetrix is a medical devices company with three commercialized products. The Company says it was spun off from the Harvard-MIT Division of Health Sciences and Technology in 1996. The Company has active R&D programs to expand into new indications and improve existing technologies.
Analysis Article • Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, NeuroMetrix...
Analysis Article • Jan 27

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

NUROUS Medical EquipmentUS Market
7D4.7%0.03%2.2%
1Y2.5%-20.4%24.8%

Return vs Industry: NURO underperformed the US Medical Equipment industry which returned 7.7% over the past year.

Return vs Market: NURO underperformed the US Market which returned 9.6% over the past year.

Price Volatility

Is NURO's price volatile compared to industry and market?
NURO volatility
NURO Average Weekly Movement2.8%
Medical Equipment Industry Average Movement8.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: NURO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NURO's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199613Shai Gozaniwww.neurometrix.com

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objectively detect, stage, and monitor peripheral neuropathies.

NeuroMetrix, Inc. Fundamentals Summary

How do NeuroMetrix's earnings and revenue compare to its market cap?
NURO fundamental statistics
Market capUS$8.98m
Earnings (TTM)-US$7.81m
Revenue (TTM)US$3.03m
3.1x
P/S Ratio
-1.2x
P/E Ratio

Is NURO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NURO income statement (TTM)
RevenueUS$3.03m
Cost of RevenueUS$1.32m
Gross ProfitUS$1.71m
Other ExpensesUS$9.52m
Earnings-US$7.81m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.79
Gross Margin56.42%
Net Profit Margin-257.38%
Debt/Equity Ratio0%

How did NURO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/01 14:51
End of Day Share Price 2025/05/01 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NeuroMetrix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Anthony VendettiMaxim Group